Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2074)	1/3/2008 4:53:37 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SCRX Also had a good UG & was up 17.43% at its intraday H, but closed up only 11.39% & isn't doing well AHs.<g> bigcharts.marketwatch.com It announced yesterday, after the market closed, that the FDA has approved all four dosage strengths of its new Sular formulation, which utilizes its patented GEOMATRIX technology. SCRX has 3Qs of double digit improvement on revenues & also has better earnings. The EE for 2007 are $1.65 vs. $1.33 in 2006 & for 2008 the earnings are expected around $1.95 SCRX trades around 1.85xBV; it has > $2 in +CF; the short ratio increased 19% in the last month & is around 11x its ADV, The stock has resistance at the 23.50 level & will probably close today's UG before it gets completely off from the DT coming from its Oct11 H at 28.83 bigcharts.marketwatch.com On a close above $29 the stock could get to test its all time H of $33 in Jan 2001 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2074)	1/16/2008 11:20:04 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CRXL is down >12% after questions about one of its patents for protein production. The stock has now more than closed its Jan 3 UG.<g> bigcharts.marketwatch.com CRXL today reacted to a press release issued by CEVEC Pharmaceuticals GmbH yesterday, in which it announced that one of CRXL's patents for protein production was restricted by a decision of the European Patent Office.(CRXL stated that the suggestions made by CEVEC are misleading.) CRXL stated that the only limitation that was made has no consequence for the scope of protection of the patent as a whole, & the essential claims of the patent for the method of producing a recombinant protein, have been maintained without any limitation. Will see if CRXL can find support at the $15 level.<g> bigcharts.marketwatch.com Bernard